This is not too much of a surprise, based upon the data revealed at ESC 2017 in August. However, it's official. Another nail in the coffin for CETP inhibitors. Long live apabetalone!
"Positive PhIII can’t salvage Merck’s anacetrapib, now relegated to the scrap heap" by John Carroll, Endpoint News